SL-22P is under clinical development by Hebei Senlang Biotechnology and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SL-22P’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SL-22P is under development for the treatment of solid tumours including refractory brain metastasis, and liver cancer. It comprises of autologous T-cells genetically engineered to express chimeric antigen receptor (CAR-T) targeting the cells expressing CD22 and armoured with anti-PD-L1. It is administered by parenteral route.
Hebei Senlang Biotechnology overview
Hebei Senlang Biotechnology is a pharamaceutial and healthcare company which is involved in using bio technology for treatment of immune cells. The company is headquartered in Dongguan, Hebei, China.
For a complete picture of SL-22P’s drug-specific PTSR and LoA scores, buy the report here.